A Diamond In The Rough

Inhibitex (NASDAQ: INHX) focuses on infectious diseases and two of its antibody-based therapies are in Phase III and Phase II clinical trials for Staphylococcus aureus (staph) infections. The company’s most advanced product candidate is Veronate, which is in a Phase III clinical trial for the prevention of staph infections in infants with very low birthweights. Veronate is targeting an unmet need, noting that 18% of these infants succumb to staph infections each year in the U.S. The primary endpoint of the pivotal Phase III trial is to demonstrate efficacy in the prevention of hospital-associated infections due to staph in this infant population.

Veronate, which is a concentrated polyclonal immune globulin, has been granted both fast- track designation and Orphan Drug status in the U.S. and has been recommended for Orphan Medicinal Product designation in Europe. The company has retained all worldwide rights to Veronate and, if it is approved, anticipates commercializing it independently in the U.S. This is huge for Inhibitex, which could stand to make a significant profit. To put this in perspective, Synagis, which is marketed by Medimmune (NASDAQ: MEDI) to treat respiratory syncytial virus infection in newborns, has reached blockbuster status and is a major revenue stream for Medimmune.

Inhibitex’s other promising candidate in clinical trials is Aurexis, a monoclonal antibody specific for Staphylococcus aureus. It is Phase II clinical as a first-line therapy, in combination with standard of care antibiotics, for treatment of serious staph bloodstream infections in hospitalized patients. Compared to patients receiving standard of care treatment alone, patients also receiving Aurexis had a shorter duration of stay in the intensive care unit and less time on mechanical ventilators. Based on these findings, Inhibitex plans to initiate additional clinical studies in this indication in 2006.

Serious staph infections represent a growing problem at hospitals, particularly as antibiotic resistance increases. In addition to the challenges these infections pose to hospitals, staph infections that are serious and often resistant to antibiotics are now appearing in the community at an increasing rate. Thus, new treatments are absolutely necessary if we are to contain the spread of antibiotic-resistant bacteria.

We believe Inhibitex will have a winner in Veronate. Early results from the Phase III clinical trial look promising, and we think will carry through the remainder of the study, which is anticipated to be completed in the second half of 2006. This by itself should be good enough to cause share price appreciation.


Information transmitted via BioSpace.com has been provided by publisher, Nadine Wong, of the "Biotech Sage Report" Investment Newsletter and all comments and opinions are solely those of Nadine Wong. Information provided is not guaranteed as to completeness or accuracy by Nadine Wong (the "Biotech Sage Report" publisher), BioSpace, Inc., or any person. Such Information is neither an offer to sell nor a solicitation to buy the securities of any company. The security portfolio of the editor of this newsletter, our employees, principals or affiliated companies may, in some instances, include securities and/or options on securities mentioned in each issue. Additional information is available upon request. Information in this publication has been obtained from sources believed to be reliable, but the accuracy, completeness and interpretation are not guaranteed. Opinions expressed are subject to change without notice. The Information and views provided by the "Biotech Sage Report" Newsletter are prepared by Nadine Wong, and in no way reflect the views or efforts of BioSpace, Inc., any of BioSpace's employees or officers. BioSpace, and BioSpace's employees and officers, as well as (www.biotechnav.com) Wong & Wong, Inc, and Wong & Wong Inc.'s employees and officers, in no way accept responsibility for any of the Newsletter's content.

While all reasonable care has been taken to ensure that the Information contained herein is presented in good faith, and is not untrue or misleading at the time of publication, BioSpace, Inc. and Nadine Wong make no representation as to its accuracy or completeness and it should not be relied upon as such. The Information is supplied on the condition that the reader or any other person receiving the Information will make his or her own determination as to its suitability for any purpose prior to any use of the Information. From time to time, BioSpace, Inc. and any officers or employees of BioSpace, Inc., as well as Nadine Wong and or (www.biotechnav.com) Wong & Wong, Inc., and any officers or employees of Wong & Wong, Inc., may, to the extent permitted by law, have a position or otherwise be interested in any transactions, in any investments (including derivatives) directly or indirectly in the subject of this report. Also BioSpace, Inc. and (www.biotechnav.com) Wong & Wong, Inc., may, from time to time solicit business from any company mentioned in this report. This report is provided solely for the information of viewers of BioSpace.com and/or viewers and subscribers of the Newsletters, who are expected to make their own investment decisions without reliance on this report. Neither BioSpace, Inc. nor any officer or employee of BioSpace, Inc., nor Nadine Wong or (www.biotechnav.com) Wong & Wong, Inc., or any officer or employee of Wong & Wong, Inc., accepts any liability whatsoever for any direct, indirect, special or consequential damages or loss arising from any use of this report or their contents. This report may not be reproduced, distributed or published by any recipient for any purpose without the prior express consent of the publishers. Nothing contained herein shall be construed as conferring by implication, estoppel or otherwise any license or right under any patent, trademark or copyright of BioSpace.com, Nadine Wong or (www.biotechnav.com) Wong & Wong, Inc., or any third party.

The value of the investment(s) to which this report relates and their income yield(s) may go up or down. The investment(s) referred to in this report may not be suitable for private investors: if you are in any doubt you should seek advice from your investment advisor. Changes in rates of currency exchange may have an adverse effect on the value, price or income of investments. Statements as to past performance of any investment are not a guide to future performance. The levels and bases of taxation can change, and if you are in doubt you should seek independent professional advice. In some cases it may be difficult for you to sell or realize your investment or to obtain reliable information about its value or the extent of the risks to which you are exposed.


Back to news